2seventy bio’s (TSVT) “Sell (D-)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of 2seventy bio (NASDAQ:TSVT) in a research note published on Friday,Weiss Ratings reports.

2seventy bio Price Performance

Shares of TSVT stock opened at $2.66 on Friday. The firm has a market cap of $137.22 million, a PE ratio of -1.43 and a beta of 1.73. The company has a 50-day moving average of $2.60 and a two-hundred day moving average of $3.70. 2seventy bio has a 1-year low of $2.29 and a 1-year high of $5.99.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Toronto Dominion Bank purchased a new position in 2seventy bio during the fourth quarter worth about $2,352,000. Western Standard LLC boosted its stake in 2seventy bio by 175.7% during the fourth quarter. Western Standard LLC now owns 788,350 shares of the company’s stock worth $2,318,000 after buying an additional 502,419 shares during the period. Stonepine Capital Management LLC boosted its stake in 2seventy bio by 200.0% during the fourth quarter. Stonepine Capital Management LLC now owns 300,000 shares of the company’s stock worth $882,000 after buying an additional 200,000 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of 2seventy bio during the fourth quarter worth about $913,000. Finally, ProShare Advisors LLC acquired a new stake in shares of 2seventy bio during the fourth quarter worth about $48,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.